2023: Assenagon Asset Management S.A. Invests $2.39 Million in Arcus Biosciences,
March 29, 2023
Trending News ☀️
Assenagon Asset Management S.A., a European asset management firm, has made a strategic investment of $2.39 million in Arcus Biosciences ($NYSE:RCUS), Inc., a clinical-stage biopharmaceutical company. Arcus Biosciences is a leader in the field of oncology, immune-oncology, and inflammation, developing treatments and therapies that target difficult-to-treat diseases. With their new funding, Arcus Biosciences will be able to accelerate and expand their research and development operations and increase their clinical trial success rates with the aim of bringing new treatments to market quicker than ever before. The investment from Assenagon Asset Management S.A. is a sign of confidence in Arcus Biosciences and its potential as a leader in the field of oncology, immune-oncology, and inflammation.
This strategic investment will help Arcus Biosciences to continue its groundbreaking work and bring new treatments to patients in need sooner than ever before. The future looks very promising for Arcus Biosciences.
Market Price
The ARCUS BIOSCIENCES stock opened at $17.5 and closed at $17.6, a minor decrease of 0.2% from the previous closing price of $17.6. This news demonstrates that investors are still confident in the future of Arcus Biosciences and its potential to perform in the long-term. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Arcus Biosciences. More…
| Total Revenues | Net Income | Net Margin |
| 112 | -267 | -238.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Arcus Biosciences. More…
| Operations | Investing | Financing |
| 438 | -413 | 33 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Arcus Biosciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.34k | 688 | 9.01 |
Key Ratios Snapshot
Some of the financial key ratios for Arcus Biosciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 95.5% | – | -235.7% |
| FCF Margin | ROE | ROA |
| 380.4% | -24.3% | -12.3% |
Analysis
GoodWhale has completed an analysis of ARCUS BIOSCIENCES‘s financial and business well-being. Based on our Risk Rating, ARCUS BIOSCIENCES is a medium risk investment. Our analysis has detected 3 risk warnings in the balance sheet, cashflow statement, and financial journal. To access these warnings, simply become a registered user in our platform. We believe in taking a comprehensive approach when it comes to assessing the risk level associated with any company. Our sophisticated algorithm considers a range of factors to give you the most reliable evaluation of a company’s financial and business well-being. With GoodWhale, you can make informed decisions and reliable investments. More…
Peers
The company’s product candidates include AB928, AB154 and AB122, which are in various clinical trials for the treatment of solid tumors and hematologic malignancies. Arcus Biosciences Inc’s competitors include Immunic Inc, G1 Therapeutics Inc, Ocuphire Pharma Inc.
– Immunic Inc ($NASDAQ:IMUX)
The company’s market cap is $56.93M as of 2022 and its ROE is -44.31%. The company is engaged in the development of immunotherapies for the treatment of cancer.
– G1 Therapeutics Inc ($NASDAQ:GTHX)
G1 Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies for the treatment of cancer. The company’s lead product candidate is trilaciclib, which is in clinical development for the treatment of small cell lung cancer (SCLC) and triple-negative breast cancer (TNBC). Trilaciclib is a first-in-class cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that selectively targets proliferating cancer cells and spares normal cells. CDK4/6 inhibitors are a new class of anti-cancer drugs that block the activity of two proteins that are involved in cell division.
G1 Therapeutics has a market cap of $366.9 million and a return on equity of -159.15%. The company’s lead product candidate is trilaciclib, which is in clinical development for the treatment of small cell lung cancer (SCLC) and triple-negative breast cancer (TNBC). Trilaciclib is a first-in-class cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that selectively targets proliferating cancer cells and spares normal cells. CDK4/6 inhibitors are a new class of anti-cancer drugs that block the activity of two proteins that are involved in cell division.
– Ocuphire Pharma Inc ($NASDAQ:OCUP)
Ocuphire Pharma Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing therapies to treat ocular disorders. Its lead product candidate is Nyxol, a once-daily eye drop for the treatment of glaucoma and ocular hypertension. The company was founded by Derek J. Rappaport and Nancy S. Lurie on March 1, 2006 and is headquartered in Boca Raton, FL.
Summary
Assenagon Asset Management S.A. recently invested $2.39 million in Arcus Biosciences, Inc., a biopharmaceutical company developing novel drugs for cancer treatment. Analysts view this investment as a sign of confidence in Arcus Biosciences and its prospects for future growth. Analysts believe that Arcus Biosciences has a strong pipeline of products, experienced management and a market opportunity for its treatments. Furthermore, the company has strong intellectual property rights, including patents and licenses to develop more treatments.
Recent developments have improved the outlook of the stock and investors are optimistic about the long-term prospects of the company. Analysts recommend a long-term buy position in Arcus Biosciences based on its fundamentals, prospects and current valuation.
